Simplex Trading, LLC Aadi Bioscience, Inc. Transaction History

Simplex Trading, LLC

$195 Billion
Q3 2025

A detailed history of Simplex Trading, LLC transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 35 shares of AADI stock, worth $59. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$59

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	BUY	N/A	35 New	35 $0
Q4 2024 Feb 11, 2025	SELL	$1.92 - $3.39 $3,419 - $6,037	-1,781 Reduced 76.14%	558 $1,000
Q3 2024 Nov 08, 2024	SELL	$1.32 - $2.06 $191 - $298	-145 Reduced 5.84%	2,339 $4,000
Q2 2024 Jul 25, 2024	BUY	$1.46 - $2.31 $1,508 - $2,386	1,033 Added 71.19%	2,484 $3,000
Q1 2024 Apr 25, 2024	SELL	$1.59 - $2.44 $5,103 - $7,832	-3,210 Reduced 68.87%	1,451 $3,000
Q4 2023 Feb 02, 2024	BUY	$1.97 - $5.41 $9,182 - $25,216	4,661 New	4,661 $9,000
Q1 2023 Apr 27, 2023	BUY	$6.85 - $13.0 $602 - $1,144	88 Added 733.33%	100 $0
Q4 2022 Feb 02, 2023	SELL	$11.99 - $14.5 $959 - $1,160	-80 Reduced 86.96%	12 $0
Q3 2022 Nov 04, 2022	BUY	$12.03 - $14.22 $1,106 - $1,308	92 New	92 $1,000
Q1 2022 May 02, 2022	SELL	$16.65 - $24.97 $1,664 - $2,497	-100 Closed	0 $0
Q4 2021 Feb 23, 2022	BUY	$19.32 - $29.02 $1,932 - $2,902	100 New	100 $2,000

Others Institutions Holding AADI

# of Institutions

Shares Held

29.4M

Call Options Held

Put Options Held

Qvt Financial LP New York, NY

4.62M
Shares

$7.89 Million
0.65% of portfolio
Orbimed Advisors LLC San Diego, CA

4.17M
Shares

$7.12 Million
0.24% of portfolio
Suvretta Capital Management, LLC New York, NY

3.7M
Shares

$6.33 Million
0.19% of portfolio
Acuta Capital Partners, LLC Belmont, CA

3.41M
Shares

$5.83 Million
10.98% of portfolio
Avoro Capital Advisors LLC New York, NY

2.85M
Shares

$4.87 Million
0.07% of portfolio

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $35.9M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account